Embedded Files
Congratulations to Tommaso Tonelli for his recent publication
Our laboratory is interested in the development of immunological treatments, and vaccines in particular, that can eradicate prostate cancer. The long-term goal of these studies is to identify in the laboratory, and test in clinical trials, vaccines that can elicit prostate cancer-destructive immune responses for the purpose of treating prostate cancer patients with minimal disease remaining after other standard therapies. This work is “translational” research, in that it uses patient-derived samples to formulate hypotheses and drive laboratory research and discovery, and then takes these laboratory findings to pre-clinical and clinical studies.
Our laboratory is interested in the development of immunological treatments, and vaccines in particular, that can eradicate prostate cancer. The long-term goal of these studies is to identify in the laboratory, and test in clinical trials, vaccines that can elicit prostate cancer-destructive immune responses for the purpose of treating prostate cancer patients with minimal disease remaining after other standard therapies. This work is “translational” research, in that it uses patient-derived samples to formulate hypotheses and drive laboratory research and discovery, and then takes these laboratory findings to pre-clinical and clinical studies.
Developing Antigen Specific DNA Vaccines as a Treatment for Prostate Cancer. Doug McNeel, MD, PhD, University of Wisconsin, Madison. Dr. McNeel is a CDMRP-funded investigator supported by the DoD Prostate Cancer Research Program (PCRP)
Developing Antigen Specific DNA Vaccines as a Treatment for Prostate Cancer. Doug McNeel, MD, PhD, University of Wisconsin, Madison. Dr. McNeel is a CDMRP-funded investigator supported by the DoD Prostate Cancer Research Program (PCRP)
Page updated
Report abuse